

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**丽珠医药**  
**LIVZON**

**麗珠醫藥集團股份有限公司**

**LIVZON PHARMACEUTICAL GROUP INC.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1513)**

## **CHANGE OF DIRECTOR**

### **1. RETIREMENT OF DIRECTOR**

The board of directors of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.\* (the “**Company**”) (the “**Board**”) announces that after the ninth session of the Board takes office, Mr. Yang Daihong will retire as an executive director of the Company with effect from 30 June 2017 due to the expiration of his tenure as a director. Mr. Yang Daihong has confirmed that he has no disagreement with the Board and there are no matters relating to his retirement that need to be brought to the attention of the shareholders of the Company. The Board would like to express its sincere gratitude to Mr. Yang Daihong for his valuable contributions to the Company’s development during his tenure.

### **2. APPOINTMENT OF NEW DIRECTOR**

At the Company’s annual general meeting for the year 2016 (the “**AGM**”) held on 23 June 2017, Mr. Xu Guoxiang (“**Mr. Xu**”) was appointed as executive director for the ninth session of the Board, whose tenure will commence from 30 June 2017 and end on the expiration of the tenure of the ninth session of the Board.

The biographical details of Mr. Xu as the newly appointed director of the Company are set out below:

Mr. Xu Guoxiang (徐國祥先生), aged 54, is currently the Vice President of the Company. From November 2010 to November 2011, Mr. Xu attended an advanced EMBA course in PRC’s pharmaceutical industry organised by the Medical School of Peking University (北京大學醫學部) and obtained a completion certificate. From 2000 to 2005, Mr. Xu was the director of Yangtze River Pharmaceutical Co., Ltd. (揚子江製藥股份有限公司). In March 2007, Mr. Xu was our Chief Sale

Supervisor and the general manager of our branch company in Henan Province. Mr. Xu has been our Vice President from December 2007 to present. He is currently the vice president of China Association of Pharmaceutical Commerce, the executive director of the Chinese Hospital Association and the council member of the Bethune Charitable Foundation.

Mr. Xu has interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), details of which are as below:

<b>Name of Director</b>	<b>Capacity</b>	<b>Number of shares Interested</b> (Long position)	<b>As a percentage to the specific class of issued shares of the Company</b>	<b>As a percentage to the total issued shares of the Company</b>
Mr. Xu	Beneficial owner	275,990 A Shares	0.10%	0.06%

Save as disclosed above, as at the date of this announcement, Mr. Xu does not hold any directorship in other listed companies at present and in the past three years preceding the date of this announcement and has no relationship with any other directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company.

Mr. Xu will receive an annual director's fee of RMB 72,000 plus an annual salary with discretionary bonus during his tenure. The director's fees are determined by reference to the duties and responsibilities of the director within the Company, the Company's remuneration policy and the market salary range for such position.

Save as disclosed above, there are no other matters in relation to the abovementioned newly appointed director that need to be brought to the attention of the shareholders of the Company, nor is there any other information required to be disclosed pursuant to any of the requirements under Rule 13.51(2) (h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board  
**Livzon Pharmaceutical Group Inc. \***  
 麗珠醫藥集團股份有限公司  
**Yang Liang**  
*Company Secretary*

Zhuhai, China  
 23 June 2017

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Yang Daihong (Vice President); the Non-executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Qiu Qingfeng and Mr. Zhong Shan; and the Independent Non-executive Directors of the Company are Mr. Xu Yanjun, Mr. Guo Guoqing, Mr. Wang Xiaojun, Mr. Zheng Zhihua and Mr. Xie Yun.*

\* For identification purpose only